Bavarian Nordic awarded a 3 year contract from the US Government  

2004.10.01
The National Institute of Allergy and Infectious Diseases has awarded the Danish biotech company a DKK 604 mn contract to further develop its safe smallpox vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded Bavarian Nordic a 3 year contract to further develop its safe smallpox vaccine Imvamune. The contract is worth DKK 604 mn (USD 100 mn). Included in the contract is delivery of 500,000 doses of Imvamune in the coming 11 months when the production process has been finally validated.

 

The US government also has an option to buy an additional 2.5 million doses of Imvamune vaccine during the contract period for DKK 248 mn (USD 41 mn). It is the second development contract NIAID has awarded Bavarian Nordic. The first was given in February 2003, followed by a supplemental contract in the same year. The new contract is not expected to affect earnings expectations for 2004 which remains at DKK 400 mn (USD 64 mn), and a profit before tax of DKK 60-80 mn (USD 9.6-12.5 mn). The news is reported by national newspaper Jyllands-Posten online.

 

Link > Bavarian Nordic 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×